Nevro raises outlook as neuromodulation market recovers from COVID-19 crisis
Dive Brief: Nevro has raised its full-year guidance after a first quarter that increased its confidence that demand for its neuromodulation devices will recover quickly. Global sales rose 1% over the first three months of the year but improvements during the quarter, which culminated in Nevros best March ever, emboldened the company to target at least 22% growth across 2021. The outlook assumes the continued easing of pandemic pressures throughout the year and the FDA approval of Nevros device ...
Source: medtechdive.com